Business Wire

CA-VELODYNE-LIDAR

30.9.2020 15:33:11 CEST | Business Wire | Press release

Share
Velodyne Lidar Announces Inaugural Trading on Nasdaq Global Select Market

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced shares of its common stock and warrants have begun trading on The Nasdaq Global Select Market under the ticker symbols “VLDR” (common stock) and “VLDRW” (warrants).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005166/en/

Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies, including revolutionary sensor and software solutions. These innovative technologies deliver performance, quality and flexibility to meet the needs of a wide range of industries such as autonomous vehicles and growing new markets. Currently, Velodyne serves the automotive industry with its broad product portfolio, providing lidar for high quality advanced driver assistance systems (ADAS) as well as for vehicle autonomy.

In addition to serving the automotive market, Velodyne is delivering lidar for new markets including smart city with smart intersections, security, mobile 3D mapping, industrial and factory robotics, smart agriculture, sidewalk delivery, drone/unmanned aerial vehicles (UAV) and more. There is a growing demand in these new markets as they ramp up business and expand. Velodyne’s lidar solutions are being utilized on a global scale by a highly diversified customer base. The company’s innovative Automated with Velodyne (AwV) program supports an integrator ecosystem to commercialize next-generation autonomous solutions using Velodyne lidar technology. Through the growing AwV program, Velodyne helps more than 65 companies by supporting innovation, promoting applications and creating lasting customer and business relationships.

Earlier this year, Velodyne named Dr. Anand Gopalan as its Chief Executive Officer. Previously serving as Velodyne’s Chief Technology Officer, Gopalan is a seasoned semiconductor executive with experience building and leading global technology companies.

“Today marks another great milestone for Velodyne, which started with the vision and ingenuity of our founder David Hall. We’ve grown into a global lidar powerhouse due to the significant contributions from our employees worldwide,” said Gopalan. “Becoming a public company enables Velodyne to invest more in delivering new transformative autonomous technology and powerful ADAS products to make our world a better place. With our broad portfolio of lidar sensors and revolutionary software, we strive to transform communities by advancing safer mobility for all.”

Jump-Starting the Autonomous Revolution

Hall invented real-time surround view lidar systems in 2005 to provide a precise vision system for autonomous vehicles competing in the DARPA Grand Challenge. Velodyne’s earliest customers, including Ford Motors, GM, Caterpillar and Google, met Hall at the DARPA Grand Challenge. Working closely with these customers, Hall continued innovate, harden and improve the original lidar design for 3D mapping and autonomous driving. Today, almost all major car makers working on safe autonomy have adapted Hall’s technology to spawn their autonomous vehicle programs, making the “autonomous revolution” possible. Other lidar companies emerged in the wake of Velodyne but have been challenged to surpass Velodyne Lidar in quality and brilliance of the original patented invention. One can today point to Hall as the instigator of the autonomous revolution which has the potential to change the direction of transportation and modern life.

The Intellectual Property Owners Education Foundation awarded Hall its 2018 Inventor of the Year award to recognize his many innovation accomplishments. In addition, the Alliance of Automobile Manufacturers (Auto Alliance) honored Hall as an Autos2050 award winner.

Velodyne is a leader in intellectual property for lidar technologies and holds an extensive portfolio of patents and patent applications. The company has served more than 300 customers in the automotive and technology industries, including nearly all the leading global automotive original equipment and technology manufacturers. Velodyne has received many industry awards for its achievements. Recent recognitions include Hardware Supplier of the Year in the 2020 TU-Automotive Awards and the prestigious 2019 Automotive News PACE Award.

Advancing Safer Mobility

Velodyne has a long-standing commitment to fostering understanding of the safety and mobility benefits of autonomous solutions to consumer, business, government, public safety and community audiences. The pinnacle of these efforts is Velodyne’s annual World Safety Summit on Autonomous Technology . The event has sparked collaborative work to advance solutions for rolling out autonomy and ADAS with the goal of safer mobility. Velodyne also partners with Mothers Against Drunk Driving and Partners for Automated Vehicle Education on public education about improving safety on roadways.

“Velodyne has the key technology that is enabling safer autonomous mobility,” said Hall. “Velodyne’s mission is to help save lives and move both people and goods more efficiently. We are also excited about the emergence of new markets as innovators discover new ways to use lidar. Today’s achievement of becoming a public company is a testament to our terrific team, our loyal customers, hard-working employees and invaluable investment partners as we ushered in a new vision and world with this technology.”

About Velodyne Lidar

Velodyne Lidar ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all.

Forward Looking Statements

This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Link:

ClickThru

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye